Combined modality therapy improves overall survival for angiosarcoma

Figures & data

Table 1. Patient characteristics and treatment information.

	Number	Percent
All patients	63
Sex
Male	28	44.4
Female	35	55.6
Age
Median: 65 years (range 21–87)
Site
Breast/chest/axilla	20	31.7
Head and neck	18	28.6
Extremity	11	17.5
Other	14	22.2
Stage
I	10	15.9
II	16	25.4
III	18	28.6
IV	7	11.1
Unknown	12	19.0
Etiology
Sporadic	47	74.6
Secondary (prior RT)	16	25.4
Initial treatment
Surgery alone	26	41.3
Surgery + adjuvant therapy	16	25.4
Neoadjuvant therapy + surgery	8	12.7
No surgery (chemo, RT, or both)	10	15.9
No treatment	3	4.8
Surgical margin (n = 50)
R0	30	60.0
Close	9	18.0
R1	7	14.0
R2	1	2.0
Unknown	3	6.0
Initial chemotherapy regimen (n = 24)
Docetaxel + gemcitabine	13	54.2
Paclitaxel (including Abraxane)	7	29.2
Other	4	16.7
Initial radiation therapy (n = 21)
Median dose: 54 Gy (range, 30–72 Gy) (includes adjuvant and neoadjuvant)
Median fraction size: 2 Gy (range, 1.5–3 Gy)

RT = radiation therapy; Gy = Gray.

Figure 1. (A) Progression-free survival from time of initial treatment (date of surgery if applicable, otherwise end of radiation therapy or end of first course of chemotherapy) via Kaplan–Meier analysis. (B) Overall survival from time of initial diagnosis via Kaplan–Meier analysis. (C) Overall survival from time of initial diagnosis by initial treatment modality via Kaplan–Meier analysis. Statistical significance via log-rank test.